XTR010 / Sinotau Pharma - LARVOL DELTA

XTR010 is a 177Lu-labeled PSMA-targeted radioligand for the treatment of mCRPC (HKEXnews) - "Different from Pluvicto, XTR010 incorporates a structurally optimized targeting ligand that enhances tumor uptake with a reduced radionuclide dose. This offers a cost advantage by achieving comparable or improved therapeutic effects with a smaller dose of radionuclide, positioning XTR010 as a promising and cost-effective treatment option for prostate cancer patients. As of the Latest Practicable Date, XTR010 stood out as the first domestically developed PSMA-targeted radiopharmaceutical to receive IND approval in China and we were advancing XTR010 in a Phase I/II clinical trial."

New P1/2 trial • Castration-Resistant Prostate Cancer

Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - P1/2 | N=32 | Recruiting | Sponsor: Sinotau Pharmaceutical Group | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - P1/2 | N=32 | Not yet recruiting | Sponsor: Sinotau Pharmaceutical Group

Metastases • New P1/2 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor